Biogen revenue trounces forecast as MS drug sales surge

July 23 Wed Jul 23, 2014 7:04am EDT

July 23 (Reuters) - Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast.

The company on Wednesday said it had earned $723.1 million, or $3.01 per share, in the second quarter. That compared with $491 million, or $2.06 per share, a year earlier, when it took a legal settlement charge.

Global revenue rose 40 percent to $2.42 billion, well above the average forecast of $2.16 billion among analysts surveyed by Thomson Reuters I/B/E/S. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article